GlassScriptPhysician profile
Sean C Liyanage
NPI 1922663228
$3,936.41
in general payments reported to CMS, 2019-2025
30 companies · $1,202 in 2025
The $1,202 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $150 · 2021: $149 · 2022: $376 · 2023: $557 · 2024: $1,223 · 2025: $1,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,822 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,822.29 |
| Education | $159.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $403.97 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $390.16 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $354.02 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $317.94 | 2020-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $288.54 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Pfizer INC. | $286.85 | 2021-2025 | |
| Astellas Pharma US INC | $279.29 | 2023-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $215.25 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $162.77 | 2019-2025 | Rexulti |
| Kci USA, INC. | $138.09 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $136.56 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $125.37 | 2022-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $97.80 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Exact Sciences Corporation | $95.31 | 2024-2025 | Cologuard Collection Kit |
| Mannkind Corporation | $94.18 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $89.49 | 2025 | Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.52 | 2024-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $76.99 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $46.20 | 2019-2022 | |
| Medtronic, INC. | $37.01 | 2022-2023 | Intellis Adaptivestim |
| Kowa Pharmaceuticals America, INC. | $29.80 | 2025 | Zoryve |
| Lucid Diagnostics INC. | $28.01 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.05 | 2025 | Jardiance |
| Xeris Pharmaceuticals, INC. | $23.06 | 2024 | Keveyis |
| Alexion Pharmaceuticals, INC. | $22.59 | 2020 | |
| Lundbeck LLC | $22.56 | 2025 | Rexulti |
| Shield Therapeutics INC | $20.44 | 2024 | |
| Inogen, INC. | $15.59 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Radius Health, INC. | $13.93 | 2023 | Tymlos |
| Biohaven Pharmaceuticals, INC. | $13.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Liyanage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.